Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis

Alcoholic hepatitis (AH) is a life-threatening condition characterized by profound hepatocellular dysfunction for which targeted treatments are urgently needed. Identification of molecular drivers is hampered by the lack of suitable animal models. By performing RNA sequencing in livers from patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Argemi, Josepmaria, Latasa, M. U, Atkinson, S. R, Blokhin, I. O, Massey, V, Gue, J. P, Cabezas, J, Lozano, Juan José, Van Booven, D, Bell, Aaron, Cao, S, Vernetti, L. A, Arab, J. P, Ventura-Cots, Meritxell, Edmunds, L. R, Fondevilla, C, Stärkel, P, Dubuquoy, L, Louvet, Alexandre, Òdena Garcia, Gemma, Gomez, J. L, Aragon, T, Altamirano, José, Caballería, J, Jurczak, M. J, Taylor, D. L, Berasain, Carmen, Wahlestedt, C, Monga, S. P, Morgan, M. Y, Sancho-Bru, P, Mathurin, Philippe, Furuya, S, Lackner, C, Rusyn, I, Shah, V. H, Thursz, M. R, Mann, J, Avila, Matias A, Bataller, Ramon, Universitat Autònoma de Barcelona
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Animals Biopsy Chromatin Assembly and Disassembly Disease Progression DNA Methylation Epigenesis, Genetic Female Gene Expression Profiling Gene Expression Regulation Hepatitis, Alcoholic Hepatocyte Nuclear Factor 4 Hepatocytes Humans Liver Male Middle Aged Polymorphism, Genetic Sequence Analysis, RNA Transforming Growth Factor beta1
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Alcoholic hepatitis (AH) is a life-threatening condition characterized by profound hepatocellular dysfunction for which targeted treatments are urgently needed. Identification of molecular drivers is hampered by the lack of suitable animal models. By performing RNA sequencing in livers from patients with different phenotypes of alcohol-related liver disease (ALD), we show that development of AH is characterized by defective activity of liver-enriched transcription factors (LETFs). TGFβ1 is a key upstream transcriptome regulator in AH and induces the use of HNF4α P2 promoter in hepatocytes, which results in defective metabolic and synthetic functions. Gene polymorphisms in LETFs including HNF4α are not associated with the development of AH. In contrast, epigenetic studies show that AH livers have profound changes in DNA methylation state and chromatin remodeling, affecting HNF4α-dependent gene expression. We conclude that targeting TGFβ1 and epigenetic drivers that modulate HNF4α-dependent gene expression could be beneficial to improve hepatocellular function in patients with AH.